Edgar Filing: AUERBACH ALAN H - Form 4

AUERBACH A Form 4										
February 06, 20										
FORM	4 UNITED ST	ATES SECH	рітіес ал			CF C	OMMISSION		PROVAL	
	UNITED ST					GEU	OMM/SSION	OMB Number:	3235-0287	
Check this b if no longer subject to Section 16.		STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF							January 31, 2005 Iverage rs per	
Form 4 or Form 5 obligations may continu <i>See</i> Instruct 1(b).	Section 17(a)	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								
(Print or Type Res	ponses)									
1. Name and Add AUERBACH	Symbol	6			5. Relationship of Reporting Person(s) to Issuer					
		[PBYI]		NOLOO	1,11	vC.	(Checl	k all applicable)	
	(First) (Mid IOTECHNOLOC VILSHIRE BLVI	(Month/J GY, 02/04/2	of Earliest Trar Day/Year) 2019	nsaction			X Director X Officer (give below) PRESID	X 10% title Othe below) DENT AND CE	er (specify	
	(Street) 4. If Amendment, I Filed(Month/Day/Ye			//Year) Applicab			Applicable Line)	dividual or Joint/Group Filing(Check icable Line) Form filed by One Reporting Person		
LOS ANGELI	ES, CA 90024						Form filed by C Form filed by M Person			
(City)	(State) (Zi	^{p)} Tab	le I - Non-De	rivative So	ecuriti	es Acqu	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Code		vispose	d of	Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
COMMON STOCK	02/04/2019		Code V S(1)	Amount 345		Price \$ 27.8	(Instr. 3 and 4) 4,165,467	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 2. 3. Transaction Date 3A. Deemed 5. 6. Date Exercisab 4. (Month/Day/Year) Derivative Conversion Execution Date, if TransactionNumber **Expiration Date** or Exercise any Code of (Month/Day/Year Price of (Month/Day/Year) (Instr. 8) Derivative Derivative Securities Security Acquired

(A) or

of (D)

Disposed

(Instr. 3, 4, and 5)

Edgar Filing: AUERBACH ALAN H - Form 4

le and	7. Title and	8. Price of	9. Nu
	Amount of	Derivative	Deriv
r)	Underlying	Security	Secu
	Securities	(Instr. 5)	Bene
	(Instr. 3 and 4)		Owne
			Follo
			Repo
			Trans
			(Instr

							Amount
				Date	Expiration		or
				Date	Expiration	Title	Number
				Exercisable	Date		of
Code	V	(A)	(D)				Shares

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
AUERBACH ALAN H C/O PUMA BIOTECHNOLOGY, INC. 10880 WILSHIRE BLVD., SUITE 2150 LOS ANGELES, CA 90024	Х	Х	PRESIDENT AND CEO			
Cimentures						

Signatures

Security

(Instr. 3)

/s/ Alan H.	
Auerbach	02/06/2019
<u>**</u> Signature of Reporting Person	Date

Explanation of Responses:

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.